



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFN α KINOID FOR TREATMENT OF LUPUS IN TURKEY

Agreement grants Centurion Pharma exclusive license to market IFN α Kinoid in Turkey

Paris and Boston, July 5th, 2017 – 7:00 AM CET – Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that the Company has signed an exclusive license agreement for IFN α Kinoid for the treatment of lupus for the territory of Turkey with **Centurion Pharma**, a regional pharmaceutical company focused on chronic disease treatments based in Ankara, Turkey.

“This license agreement follows our similar agreements with CKD Pharma in South Korea and BioSense Global in China,” said Miguel Sieler, CEO of Neovacs. *“These 3 agreements are indicative of the significant market interest in our IFN α Kinoid technology and support Neovacs’ position in our discussions with major pharmaceutical groups for a global licence deal. Centurion Pharma has extensive experience in the vaccine & specialty therapeutic care markets, and we are pleased to leverage their expertise in this area, as well as their strong track record in order to introduce this innovative treatment for Lupus in Turkey. Our license agreement with Centurion is representative of our strategy to identify high-quality local partners to support our objective of accelerating the development and commercialization of our most advanced vaccine, IFN α Kinoid. In addition, the agreement provides Neovacs with the opportunity to monetize our lead asset through an upfront payment and potential milestone payments, as well as a royalty stream.”*

Centurion will enter into negotiation with local health authorities in Turkey in order to obtain an agreement to commercialize IFN α Kinoid in lupus on a “Named Patients” program basis, following the success of Neovacs’ Phase IIb clinical trial in lupus.

Under the terms of this agreement, Neovacs will receive a total of €6 million, including an upfront payment at signature and additional potential payments based on the achievement of predefined clinical and regulatory milestones. In addition, Neovacs will also receive double digit royalties on net sales of IFN α Kinoid in Turkey. Neovacs and Centurion also intend to finalize a product supply agreement for IFN α Kinoid shortly.

About Centurion Pharma

Since 1979, Centurion has been serving the Turkish market with therapeutic care products for the treatment of specific and rare diseases encountered in Turkey as well as biological, biotechnological and hospital products through collaborations with leading pharmaceuticals of the world. Centurion head office is located in Istanbul and the Company will expand its production activities in Ankara for biosimilars, vaccines, orphan drugs and hospital generics at the end of 2017. The R&D activities are located at the Centurion production area with a main focus on specific therapeutic areas. The company will expand the business for neighborhood countries like Middle East, CIS, Africa and Balkan countries after the start of local production.

<http://www.centurion.com.tr/>

About Neovacs

Listed on Euronext Growth Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α -Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

ActeaVentures acted as a business development consultant for Neovacs

About ActeaVentures GmbH

ActeaVentures is a global business development advisory firm for the Life Sciences Industry serving clients in pharma, biotech, diagnostics and medtech, with offices in Europe (Germany, Spain, France), USA (San Francisco, Boston) and Asia (Singapore, China, Japan). <http://www.acteaventures.com>

Contacts

NEOVACS – Corporate Communication & Investor Relations

Charlène Masson

+33 (0)1 53 10 93 14

cmasson@neovacs.com

NEWCAP- Press relations

Annie-Florence Loyer

+33 1 44 71 00 12 / + 33 6 88 20 35 59

afloyer@newcap.fr

Léa Jacquin

+33 1 44 71 20 41 / +33 6 58 14 84 66

ljacquin@newcap.fr

LIFESCI ADVISORS- Investor Relations / Financial Communications

Chris Maggos

+41 79 367 6254

chris@lifesciadvisors.com